LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Zurück zur letzten Suche Suchhistorie
Erweiterte Suche

Ihre letzten Suchen

  1. AU="van Deventer, Anneen"
  2. AU="Dodd, Alyson L"
  3. AU="Garland, Alexandra"
  4. AU="Céline Chauleur"
  5. AU="Savic, Ivana"
  6. AU="Koçak, Emine Eren"
  7. AU="Azreen Hashim, Nurul"
  8. AU="Alvarez, Abel V. Jr" AU="Alvarez, Abel V. Jr"
  9. AU="Boboshko, Vladimir A"
  10. AU=Zweig Ann S AU=Zweig Ann S
  11. AU="Fortea, Jose Ignacio"
  12. AU="Graeme S. Cumming"
  13. AU="Field, Belinda G"
  14. AU="Erhart, Stephen"
  15. AU="Glenn Smith"
  16. AU="Shillingford, Shanelle R"
  17. AU="Ahn, Sung Soo"
  18. AU="Salih, Harith M"
  19. AU="Clayton, Philip A"
  20. AU="Soto, A. Garcia"
  21. AU="Jones, Daniel OB"
  22. AU="Chen, Maosheng"
  23. AU="Li, Zhengxi"
  24. AU="Toshiya Takahashi"
  25. AU=Hickey Chelsea L.
  26. AU="Badhrinarayanan, Shreya"
  27. AU="Milani, Liliana"
  28. AU="Reinhardt, Klaus"
  29. AU="Caudillo-Flores, Uriel"
  30. AU="Yin, Yizhen"
  31. AU=Kaushansky Kenneth
  32. AU="Golla, Jaya Prakash"
  33. AU="Penn, Marc S"
  34. AU="Montero, Vincent"
  35. AU="Etevenon, Pierre"
  36. AU="Hyseni, Agon"
  37. AU="Seitzman, Natalie"
  38. AU="Loukil, Abdelhalim"
  39. AU="Giammusso, Bruno"
  40. AU="Kaplan, Jonathan E"
  41. AU=Francolini Giulio
  42. AU="Yuhu Li"
  43. AU=Kim Moojung
  44. AU="Vise, Luciana M"
  45. AU="Marcinowska, Zuzanna"
  46. AU="Graff, Pablo"

Suchergebnis

Treffer 1 - 4 von insgesamt 4

Suchoptionen

  1. Artikel ; Online: Comprehensive profiling of pre-infection antibodies identifies HIV targets associated with viremic control and viral load.

    Grant-McAuley, Wendy / Morgenlander, William / Hudelson, Sarah E / Thakar, Manjusha / Piwowar-Manning, Estelle / Clarke, William / Breaud, Autumn / Blankson, Joel / Wilson, Ethan / Ayles, Helen / Bock, Peter / Moore, Ayana / Kosloff, Barry / Shanaube, Kwame / Meehan, Sue-Ann / van Deventer, Anneen / Fidler, Sarah / Hayes, Richard / Ruczinski, Ingo /
    Kammers, Kai / Laeyendecker, Oliver / Larman, H Benjamin / Eshleman, Susan H

    Frontiers in immunology

    2023  Band 14, Seite(n) 1178520

    Abstract: Background: High HIV viral load (VL) is associated with increased transmission risk and faster disease progression. HIV controllers achieve viral suppression without antiretroviral (ARV) treatment. We evaluated viremic control in a community-randomized ... ...

    Abstract Background: High HIV viral load (VL) is associated with increased transmission risk and faster disease progression. HIV controllers achieve viral suppression without antiretroviral (ARV) treatment. We evaluated viremic control in a community-randomized trial with >48,000 participants.
    Methods: A massively multiplexed antibody profiling system, VirScan, was used to quantify pre- and post-infection antibody reactivity to HIV peptides in 664 samples from 429 participants (13 controllers, 135 viremic non-controllers, 64 other non-controllers, 217 uninfected persons). Controllers had VLs <2,000 copies/mL with no ARV drugs detected at the first HIV-positive visit and one year later. Viremic non-controllers had VLs 2,000 copies/mL with no ARV drugs detected at the first HIV-positive visit. Other non-controllers had either ARV drugs detected at the first HIV-positive visit (n=47) or VLs <2,000 copies/mL with no ARV drugs detected at only one HIV-positive visit (n=17).
    Results: We identified pre-infection HIV antibody reactivities that correlated with post-infection VL. Pre-infection reactivity to an epitope in the HR2 domain of gp41 was associated with controller status and lower VL. Pre-infection reactivity to an epitope in the C2 domain of gp120 was associated with non-controller status and higher VL. Different patterns of antibody reactivity were observed over time for these two epitopes.
    Conclusion: These studies suggest that pre-infection HIV antibodies are associated with controller status and modulation of HIV VL. These findings may inform research on antibody-based interventions for HIV treatment.
    Mesh-Begriff(e) Humans ; Viral Load ; HIV Antibodies ; Anti-Retroviral Agents/therapeutic use ; Epitopes ; Viremia/drug therapy ; HIV-1 ; HIV Infections/drug therapy
    Chemische Substanzen HIV Antibodies ; Anti-Retroviral Agents ; Epitopes
    Sprache Englisch
    Erscheinungsdatum 2023-09-06
    Erscheinungsland Switzerland
    Dokumenttyp Randomized Controlled Trial ; Journal Article ; Research Support, N.I.H., Intramural ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 2606827-8
    ISSN 1664-3224 ; 1664-3224
    ISSN (online) 1664-3224
    ISSN 1664-3224
    DOI 10.3389/fimmu.2023.1178520
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  2. Artikel ; Online: Evaluation of multi-assay algorithms for identifying individuals with recent HIV infection: HPTN 071 (PopART).

    Grant-McAuley, Wendy / Klock, Ethan / Laeyendecker, Oliver / Piwowar-Manning, Estelle / Wilson, Ethan / Clarke, William / Breaud, Autumn / Moore, Ayana / Ayles, Helen / Kosloff, Barry / Shanaube, Kwame / Bock, Peter / Mandla, Nomtha / van Deventer, Anneen / Fidler, Sarah / Donnell, Deborah / Hayes, Richard / Eshleman, Susan H

    PloS one

    2021  Band 16, Heft 12, Seite(n) e0258644

    Abstract: Background: Assays and multi-assay algorithms (MAAs) have been developed for population-level cross-sectional HIV incidence estimation. These algorithms use a combination of serologic and/or non-serologic biomarkers to assess the duration of infection. ... ...

    Abstract Background: Assays and multi-assay algorithms (MAAs) have been developed for population-level cross-sectional HIV incidence estimation. These algorithms use a combination of serologic and/or non-serologic biomarkers to assess the duration of infection. We evaluated the performance of four MAAs for individual-level recency assessments.
    Methods: Samples were obtained from 220 seroconverters (infected <1 year) and 4,396 non-seroconverters (infected >1 year) enrolled in an HIV prevention trial (HPTN 071 [PopART]); 28.6% of the seroconverters and 73.4% of the non-seroconverters had HIV viral loads ≤400 copies/mL. Samples were tested with two laboratory-based assays (LAg-Avidity, JHU BioRad-Avidity) and a point-of-care assay (rapid LAg). The four MAAs included different combinations of these assays and HIV viral load. Seroconverters on antiretroviral treatment (ART) were identified using a qualitative multi-drug assay.
    Results: The MAAs identified between 54 and 100 (25% to 46%) of the seroconverters as recently-infected. The false recent rate of the MAAs for infections >2 years duration ranged from 0.2%-1.3%. The MAAs classified different overlapping groups of individuals as recent vs. non-recent. Only 32 (15%) of the 220 seroconverters were classified as recent by all four MAAs. Viral suppression impacted the performance of the two LAg-based assays. LAg-Avidity assay values were also lower for seroconverters who were virally suppressed on ART compared to those with natural viral suppression.
    Conclusions: The four MAAs evaluated varied in sensitivity and specificity for identifying persons infected <1 year as recently infected and classified different groups of seroconverters as recently infected. Sensitivity was low for all four MAAs. These performance issues should be considered if these methods are used for individual-level recency assessments.
    Mesh-Begriff(e) Adult ; Anti-HIV Agents/therapeutic use ; Antiretroviral Therapy, Highly Active ; Cross-Sectional Studies ; Female ; HIV Infections/diagnosis ; HIV Infections/drug therapy ; HIV Infections/epidemiology ; HIV Infections/virology ; HIV-1/immunology ; Humans ; Immunoenzyme Techniques ; Incidence ; Male ; Middle Aged ; Sensitivity and Specificity ; Seroconversion ; South Africa/epidemiology ; Time Factors ; Viral Load/drug effects ; Zambia/epidemiology
    Chemische Substanzen Anti-HIV Agents
    Sprache Englisch
    Erscheinungsdatum 2021-12-17
    Erscheinungsland United States
    Dokumenttyp Clinical Trial ; Journal Article ; Research Support, N.I.H., Extramural ; Research Support, N.I.H., Intramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 2267670-3
    ISSN 1932-6203 ; 1932-6203
    ISSN (online) 1932-6203
    ISSN 1932-6203
    DOI 10.1371/journal.pone.0258644
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  3. Artikel ; Online: Evaluation of multi-assay algorithms for cross-sectional HIV incidence estimation in settings with universal antiretroviral treatment.

    Grant-McAuley, Wendy / Laeyendecker, Oliver / Monaco, Daniel / Chen, Athena / Hudelson, Sarah E / Klock, Ethan / Brookmeyer, Ron / Morrison, Douglas / Piwowar-Manning, Estelle / Morrison, Charles S / Hayes, Richard / Ayles, Helen / Bock, Peter / Kosloff, Barry / Shanaube, Kwame / Mandla, Nomtha / van Deventer, Anneen / Ruczinski, Ingo / Kammers, Kai /
    Larman, H Benjamin / Eshleman, Susan H

    BMC infectious diseases

    2022  Band 22, Heft 1, Seite(n) 838

    Abstract: Background: Multi-assay algorithms (MAAs) are used to estimate population-level HIV incidence and identify individuals with recent infection. Many MAAs use low viral load (VL) as a biomarker for long-term infection. This could impact incidence estimates ...

    Abstract Background: Multi-assay algorithms (MAAs) are used to estimate population-level HIV incidence and identify individuals with recent infection. Many MAAs use low viral load (VL) as a biomarker for long-term infection. This could impact incidence estimates in settings with high rates of early HIV treatment initiation. We evaluated the performance of two MAAs that do not include VL.
    Methods: Samples were collected from 219 seroconverters (infected < 1 year) and 4376 non-seroconverters (infected > 1 year) in the HPTN 071 (PopART) trial; 28.8% of seroconverter samples and 73.2% of non-seroconverter samples had VLs ≤ 400 copies/mL. Samples were tested with the Limiting Antigen Avidity assay (LAg) and JHU BioRad-Avidity assays. Antibody reactivity to two HIV peptides was measured using the MSD U-PLEX assay. Two MAAs were evaluated that do not include VL: a MAA that includes the LAg-Avidity assay and BioRad-Avidity assay (LAg + BR) and a MAA that includes the LAg-Avidity assay and two peptide biomarkers (LAg + PepPair). Performance of these MAAs was compared to a widely used MAA that includes LAg and VL (LAg + VL).
    Results: The incidence estimate for LAg + VL (1.29%, 95% CI: 0.97-1.62) was close to the observed longitudinal incidence (1.34% 95% CI: 1.17-1.53). The incidence estimates for the other two MAAs were higher (LAg + BR: 2.56%, 95% CI 2.01-3.11; LAg + PepPair: 2.84%, 95% CI: 1.36-4.32). LAg + BR and LAg + PepPair also misclassified more individuals infected > 2 years as recently infected than LAg + VL (1.2% [42/3483 and 1.5% [51/3483], respectively, vs. 0.2% [6/3483]). LAg + BR classified more seroconverters as recently infected than LAg + VL or LAg + PepPair (80 vs. 58 and 50, respectively) and identified ~ 25% of virally suppressed seroconverters as recently infected.
    Conclusions: The LAg + VL MAA produced a cross-sectional incidence estimate that was closer to the longitudinal estimate than two MAAs that did not include VL. The LAg + BR MAA classified the greatest number of individual seroconverters as recently infected but had a higher false recent rate.
    Mesh-Begriff(e) Humans ; Cross-Sectional Studies ; Incidence ; HIV Infections/drug therapy ; HIV Infections/epidemiology ; Immunoenzyme Techniques ; Anti-Retroviral Agents/therapeutic use ; Viral Load ; Algorithms ; Biomarkers
    Chemische Substanzen Anti-Retroviral Agents ; Biomarkers
    Sprache Englisch
    Erscheinungsdatum 2022-11-11
    Erscheinungsland England
    Dokumenttyp Journal Article
    ZDB-ID 2041550-3
    ISSN 1471-2334 ; 1471-2334
    ISSN (online) 1471-2334
    ISSN 1471-2334
    DOI 10.1186/s12879-022-07850-0
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  4. Artikel ; Online: Determination of HIV status and identification of incident HIV infections in a large, community-randomized trial: HPTN 071 (PopART).

    Eshleman, Susan H / Piwowar-Manning, Estelle / Wilson, Ethan A / Lennon, Denni / Fogel, Jessica M / Agyei, Yaw / Sullivan, Philip A / Weng, Lei / Moore, Ayana / Laeyendecker, Oliver / Kosloff, Barry / Bwalya, Justin / Maarman, Gerald / van Deventer, Anneen / Floyd, Sian / Bock, Peter / Ayles, Helen / Fidler, Sarah / Hayes, Richard /
    Donnell, Deborah

    Journal of the International AIDS Society

    2020  Band 23, Heft 2, Seite(n) e25452

    Abstract: Introduction: The HPTN 071 (PopART) trial evaluated the impact of an HIV combination prevention package that included "universal testing and treatment" on HIV incidence in 21 communities in Zambia and South Africa during 2013-2018. The primary study ... ...

    Abstract Introduction: The HPTN 071 (PopART) trial evaluated the impact of an HIV combination prevention package that included "universal testing and treatment" on HIV incidence in 21 communities in Zambia and South Africa during 2013-2018. The primary study endpoint was based on the results of laboratory-based HIV testing for> 48,000 participants who were followed for up to three years. This report evaluated the performance of HIV assays and algorithms used to determine HIV status and identify incident HIV infections in HPTN 071, and assessed the impact of errors on HIV incidence estimates.
    Methods: HIV status was determined using a streamlined, algorithmic approach. A single HIV screening test was performed at centralized laboratories in Zambia and South Africa (all participants, all visits). Additional testing was performed at the HPTN Laboratory Center using antigen/antibody screening tests, a discriminatory test and an HIV RNA test. This testing was performed to investigate cases with discordant test results and confirm incident HIV infections.
    Results: HIV testing identified 978 seroconverter cases. This included 28 cases where the participant had acute HIV infection at the first HIV-positive visit. Investigations of cases with discordant test results identified cases where there was a participant or sample error (mixups). Seroreverter cases (errors where status changed from HIV infected to HIV uninfected, 0.4% of all cases) were excluded from the primary endpoint analysis. Statistical analysis demonstrated that exclusion of those cases improved the accuracy of HIV incidence estimates.
    Conclusions: This report demonstrates that the streamlined, algorithmic approach effectively identified HIV infections in this large cluster-randomized trial. Longitudinal HIV testing (all participants, all visits) and quality control testing provided useful data on the frequency of errors and provided more accurate data for HIV incidence estimates.
    Mesh-Begriff(e) AIDS Serodiagnosis/methods ; Adult ; Algorithms ; Data Accuracy ; Female ; HIV Infections/diagnosis ; HIV Infections/epidemiology ; HIV Infections/prevention & control ; Humans ; Incidence ; Male ; Mass Screening ; Randomized Controlled Trials as Topic ; South Africa/epidemiology ; Zambia/epidemiology
    Sprache Englisch
    Erscheinungsdatum 2020-03-11
    Erscheinungsland Switzerland
    Dokumenttyp Evaluation Study ; Journal Article ; Research Support, N.I.H., Extramural ; Research Support, N.I.H., Intramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 2467110-1
    ISSN 1758-2652 ; 1758-2652
    ISSN (online) 1758-2652
    ISSN 1758-2652
    DOI 10.1002/jia2.25452
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Zum Seitenanfang